Drug profile · INN
isatuximab
SARCLISA
isatuximab (SARCLISA) is a lymphocyte differentiation antigen cd38 inhibitor.
EMA: approved PMDA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01XC38
Patents linked 0
Pipeline programs 21
News articles 0
Drug details — isatuximab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 21
- Data quality
- 0.83
Quick answer
isatuximab (SARCLISA) is a lymphocyte differentiation antigen cd38 inhibitor.
Key facts
INN isatuximab
Brand SARCLISA
Mechanism Lymphocyte differentiation antigen CD38 inhibitor
Target ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XC38
Mechanism of action
Lymphocyte differentiation antigen CD38 inhibitor
Primary target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is isatuximab?
isatuximab (SARCLISA) is a lymphocyte differentiation antigen cd38 inhibitor.
What is the brand name for isatuximab?
SARCLISA is a marketed brand name for isatuximab. Check FDA Drugs@FDA for the current US label holder and prescribing information.